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The  Bcl10 gene, mapping to human chromosome 1p22, has
recently been shown to be disrupted by translocations in MALT
lymphomas carrying a t(1;14)(p22;q32) translocation (Willis et al,
1999). These translocations map upstream of the coding sequences
of  Bcl10 and are accompanied by protein truncating mutations
within the coding sequence itself. Wild-type Bcl10 appears to
function as regulatory molecule in pro-apoptotic pathways,
whereas mutant Bcl10 alleles have been reported to have trans-
forming activity in cell culture (Willis et al, 1999). In addition to
its apparent role in MALT lymphoma, it has been reported that
Bcl10 is frequently mutated in multiple tumour types and that
inactivation of the Bcl10 gene may be a common facet in the
pathogenesis of human cancers (Willis et al, 1999). In order to
address more critically the potential role of Bcl10 in human
cancers, we have studied a series of adult carcinomas for muta-
tions in this locus. Specifically, a panel of 174 cancers targeted
primarily to those tumours reported to have frequent involvement
of the 1p22 region from prior molecular genetic studies was exam-
ined (Jin et al, 1990; Bardi et al, 1995; Hoggard et al, 1995;
Mertens et al, 1997; Tsukamoto et al, 1998; Tong and Futreal,
manuscript in preparation). The screening panel was comprised of
breast, ovarian, endometrial, cervical, colorectal and head/neck
carcinomas (Table 1).
MATERIALS AND METHODS
Genomic DNA was extracted from frozen tumours using the
PureGene kit (Gentra Systems Inc., Minneapolis, MN, USA).
Screening for mutations was carried out using single-strand
conformation analysis (SSCA) followed by direct sequencing. The
polymerase chain reaction (PCR) amplimers used in the analysis
were identical to those from Willis et al (1999) and allowed for
screening of both coding sequences and intron–exon borders of the
three coding exons of Bcl10. Standard reaction conditions
(annealing at 55°C) were used with radioactive label incorporation
as described previously (Phelan et al, 1996), except for exon 1 for
which a touchdown (annealing from 65°C to 55°C, stepdown
of 0.5°C) reaction profile was used. PCR products were denatured
in formamide-loading buffer, cooled rapidly and loaded onto
0.5  ´ MDE gels which were run overnight at 5–8 W. Gels were
dried and autoradiographed. Any aberrantly migrating bands were
excised from the gels and direct sequenced using the PCR
amplimers on an ABI-Prizm 377 sequencer as previously
described (Phelan et al., 1996).
RESULTS AND DISCUSSION
No mutations were detected in exons 2 and 3 in any of the samples
analysed. Analysis of exon 1 revealed what was most likely a
complex polymorphism on SSCA analysis given the frequency of
aberrant shifts. Direct sequencing of a subset of the prominent
shifts detected the following two polymorphisms: G13T/Ala5Ser
and G24C/Leu8Leu. Given the common nature of these changes
and the fact that one encodes a silent amino change, these most
likely represent benign polymorphisms and not deleterious
changes.
Our data do not support the notion that Bcl10 is a frequent target
of inactivation in human cancer, or that it is unusually susceptible
to mutation as has been suggested. Our analysis was restricted to
genomic DNAs derived from primary tumours as opposed to
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Summary The recently described Bcl10 gene has been suggested to be a major target gene for inactivation in a variety of human cancers. In
order to further evaluate the role of this gene in human adult malignancies, we have analysed a series of carcinomas for mutations in the
Bcl10 gene. We have screened a panel of 174 carcinoma samples in total, comprised of 47 breast, 36 epithelial ovarian, 36 endometrial,
12 cervical, 23 colorectal and 20 head/neck carcinomas, all unselected for grade or stage. This panel reflects, in part, tumours reported to
have involvement of the 1p22 region of chromosome 1, the region harbouring the Bcl10 gene. No deleterious mutations were detected in any
of the samples analysed, strongly suggesting that Bcl10 is not a common target for inactivation in adult malignancies and that BCL10 is not
the gene targeted for frequent inactivation at 1p22.
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Table 1 Carcinoma panel screened for Bcl10 mutations
Tumour type Number examined
Breast cancer 47





Total: 174analysis of cell lines in the original study, and thus the differences
reported here may be, in part, attributable to acquisition of muta-
tions in cell culture. Additionally, it is not clear what fraction of
mutations detected previously were found only in cDNA, another
factor that may influence the rate of mutation seen, as alterations
in transcripts derived from tumours have been reported that do not
correspond to bona fide genomic alterations of the target gene
(Carney et al, 1998). Our data would further suggest that Bcl10 is
not the critical 1p22 gene targeted for inactivation in multiple
tumour types.
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